ReviewChinese journal of cancer2011
Implication of platelet-derived growth factor receptor alpha in prostate cancer skeletal metastasis.
Review in Chinese journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- An In Vitro Evaluation and Network Pharmacology Analysis of Prospective Anti-Prostate Cancer Activity fromPlants (Basel, Switzerland) · 2023Article
- Role of FRG1 in predicting the overall survivability in cancers using multivariate based optimal model.Scientific reports · 2021Article
- Radium-223 mechanism of action: implications for use in treatment combinations.Nature reviews. Urology · 2019Review
- Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.BMC cancer · 2019Article
- Gli1, a potential cancer stem cell marker, is strongly associated with prognosis in prostate cancer.International journal of clinical and experimental pathology · 2018Article
- Differential Roles of Carboxylated and Uncarboxylated Osteocalcin in Prostate Cancer Growth.Journal of Cancer · 2016Article
- PKCε Is an Essential Mediator of Prostate Cancer Bone Metastasis.Molecular cancer research : MCR · 2015Article
- Platelet-derived growth factors induced lymphangiogenesis: evidence, unanswered questions and upcoming challenges.Archives of medical science : AMS · 2015Article
- Article
- Integrative molecular profiling reveals asparagine synthetase is a target in castration-resistant prostate cancer.The American journal of pathology · 2012Article
- Article
- Platelet-derived growth factor signaling in human malignancies.Chinese journal of cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metastasis represents by far the most feared complication of prostate carcinoma and is the main cause of death for patients. The skeleton is frequently targeted by disseminated cancer cells and represents the sole site of spread in more than 80% of prostate cancer cases. Compatibility between select malignant phenotypes and the microenvironment of colonized tissues is broadly recognized as the culprit for the organ-tropism of cancer cells. Here, we review our recent studies showing that the expression of platelet-derived growth factor receptor alpha (PDGFRα) supports the survival and growth of prostate cancer cells in the skeleton and that the soluble fraction of bone marrow activates PDGFRα in a ligand-independent fashion. Finally, we offer pre-clinical evidence that this receptor is a viable target for therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.